Moderna has encountered resistance from
the FDA, which consistently rejected the review of the company's mRNA
flu vaccine application. Officials defended their decision, sparking debate within the healthcare industry. Moderna critiqued the FDA's inconsistent feedback, claiming the refusal contradicts federal rules and prior guidance. However, this FDA refusal didn't seem to dampen Moderna's
financial performance. Their
Q4 losses narrowed to US$200 Million, challenging bearish profitability narratives, and Moderna exceeded its Q4 2025 expectations, all while encountering a decrease in R&D spending. This complicated situation led Moderna to seek growth outside of the US. While the refusal was a setback for Moderna's
vaccine pipeline, their sales beat expectations as their Covid shot demand fell less than anticipated. Still, experts are concerned about how this refusal might impact other research. Despite the
regulatory setbacks, Moderna is moving forward with international operations and reaffirmed its growth progress. Additionally, the rejections have incited controversy involving FDA vaccines chief
Vinay Prasad and Moderna's internal operations.
Moderna MRNA News Analytics from Wed, 17 Dec 2025 08:00:00 GMT to Sat, 14 Feb 2026 19:09:21 GMT -
Rating -8
- Innovation 2
- Information 7
- Rumor -5
